Core Insights - Inspira Technologies has received U.S. Patent approval for its low flow rates extracorporeal oxygenation system, which is central to the ART500 device, targeting a $20 billion market for advanced respiratory support [1][2][3] Company Overview - Inspira Technologies is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions, with its ART100 system already cleared by the FDA for cardiopulmonary bypass and ECMO procedures [4] - The ART500 system is designed to provide oxygenation while patients remain awake and spontaneously breathing, expanding the potential market by addressing an underserved patient population [2][4] Intellectual Property and Market Position - The newly granted patent protects the ART500's functionality, design, and clinical applications until at least 2043, enhancing the company's intellectual property portfolio and reinforcing its technological leadership [3][4] - The patent approval is seen as a critical component of the company's growth strategy, providing a competitive advantage and a pathway to long-term value for shareholders [3][4] Future Prospects - The company is pursuing additional patents in major jurisdictions worldwide to further expand its intellectual property coverage, indicating a proactive approach to securing its market position [3][4]